NewsBenzingaReported Saturday, Johnson & Johnson Says Patient Insights From Phase 2 DAHLIAS Study Helped Inform Phase 3 Nipocalimab Design, With 73.5% Of Interviewed Patients Satisfied Or Very Satisfied With Treatment In Sjögren’s Disease Reported Saturday, Johnson & Johnson Says Patient Insights From Phase 2 DAHLIAS Study Helped Inform Phase 3 Nipocalimab Design, With 73.5% Of Interviewed Patients Satisfied Or Very Satisfied With Treatment In Sjögren’s Disease Benzinga 2026.11.09 08:38 (GMT+0) Open on Benzinga Other news ‘The Odds Are Almost Zero’: Scott Galloway Doesn’t See Jensen Huang Returning to Nvidia Analysis: Hyperliquid's Stock and Commodity Trading Revenue Grows 6x, Reducing Reliance on Crypto Market Grayscale: Multiple Factors Have Turned Crypto Valuations Oversold; Current Levels Are a Medium- to Long-Term Buying Opportunity for Bitcoin Bitcoin Lightning Network Developers Patch LND Flaw That Could Wipe Payment Records After Node Restart Canton Strategic Holdings Q3 Revenue of $3.05M, Net Loss Widens to $35.1M StablecoinX Q3 Revenue Reaches $478,000, Net Loss $100 Million
Analysis: Hyperliquid's Stock and Commodity Trading Revenue Grows 6x, Reducing Reliance on Crypto Market
Grayscale: Multiple Factors Have Turned Crypto Valuations Oversold; Current Levels Are a Medium- to Long-Term Buying Opportunity for Bitcoin
Bitcoin Lightning Network Developers Patch LND Flaw That Could Wipe Payment Records After Node Restart